ସିମେପ୍ରେଭିର

ସିମେପ୍ରେଭିର
Clinical data
Pronunciation	sim-E-pre-vir
Trade names	ବ୍ୟବସାୟୀକ ନାମ - ଓଲିସିଓ, ସୋଭ୍ରିଆଡ, ଗାଲେକ୍ସୋସ ଓ ଅନ୍ୟାନ୍ୟ ।
Synonyms	TMC435; TMC435350
AHFS/Drugs.com	monograph
MedlinePlus	a614013
Pregnancy; category	US: C and X ; ;
Routes of; administration	ପାଟିରେ କ୍ୟାପସୁଲ ଆକାରରେ
ATC code	J05AE14 (WHO) ;
Legal status
Legal status	US: Rx-କେବଳ ପ୍ରେସକ୍ରିପନରେ ; ℞-କେବଳ ପ୍ରେସକ୍ରିପନରେ;
Pharmacokinetic data
Bioavailability	୬୨% (under fed conditions)
Protein binding	>୯୯.୯%
Metabolism	ଯକୃତ (CYP3A, CYP2C8, CYP2C19)
Elimination half-life	୧୦–୧୩ ଘଣ୍ଟା (ଏଚସିଭି-ଅଣସଂକ୍ରମିତ ଲୋକ), ୪୧ ଘଣ୍ଟା (ଏଚସିଭି-ସଂକ୍ରମିତ ଲୋକ)
Excretion	ମଳ (୯୧%), ପରିସ୍ରା (<୧%)
Identifiers
	IUPAC name (2R,3aR,10Z,11aS,12aR,14aR)-N-(Cyclopropylsulfonyl)-2-{[2-(4-isopropyl-1,3-thiazol-2-yl)-7-methoxy-8-methyl-4-quinolinyl]oxy}-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide;
CAS Number	923604-59-5;
PubChem CID	56928193;
IUPHAR/BPS	7367;
DrugBank	DB06290;
ChemSpider	23331536;
UNII	9WS5RD66HZ;
KEGG	D10081;
ChEMBL	CHEMBL501849;
NIAID ChemDB	489101;
ECHA InfoCard	100.215.933
Chemical and physical data
Formula	C38H47N5O7S2
Molar mass	749.94 g/mol
3D model (JSmol)	Interactive image;
	SMILES Cc1c(ccc2c1nc(cc2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)c7nc(cs7)C(C)C)OC;
	InChI InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1; Key:JTZZSQYMACOLNN-VDWJNHBNSA-N;

ସିମେପ୍ରେଭିର (ଇଂରାଜୀ ଭାଷାରେ Simeprevir), ଏହାର ଏକ ବିକ୍ରୟ ନାମ ଓଲିସିଓ, ଏକ ଔଷଧ ଯାହା ହେପାଟାଇଟିସ ସି ରୋଗର ଚିକିତ୍ସା ନିମନ୍ତେ ଅନ୍ୟ ଔଷଧ ସ‌ହିତ ଦିଆଯାଏ । ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ହେପାଟାଇଟିସ ସି ଜେନୋଟାଇପ ୧ ଓ ୪ ନିମନ୍ତେ ବ୍ୟବ‌ହାର କରାଯାଏ । ଏହା ସୋଫୋସବୁଭିର (sofosbuvir) ବା ରିବିଭିରିନ (ribavirin) ଓ ପେଜିଣ୍ଟରଫେରନ-ଆଲଫା (peginterferon-alfa) ସ‌ହିତ ଦିଆଯାଏ । ^[୧] ଏହାର ଆରୋଗ୍ୟ ହାର ପ୍ରାୟ ୮୦ରୁ ୯୦% ।^[୨]^[୩]^[୪] ଏଚଆଇଭି/ଏଡସ ରୋଗରେ ମଧ୍ୟ ଏହା ଦିଆଯାଏ । ଦିନ‌କୁ ଥରେ ୧୨ସପ୍ତାହ ପର୍ଯ୍ୟନ୍ତ ପାଟିରେ ଏହା ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପ୍ରତିକ୍ରିୟା ମଧ୍ୟରେ ଥକ୍କା ଲାଗିବା, ମୁଣ୍ଡବଥା, ରାସ, ଗଲୁ ଓ ସୂର୍ଯ୍ୟାଲୋକ ସମ୍ଭେଦନଶୀଳତା ଉତ୍ୟାଦି ଲକ୍ଷଣ ଦେକାଯାଏ । ପୂର୍ବରୁ ହେପାଟାଇଟିସ ବି ଥିଲେ ପୁନରାବୃତ୍ତି ହୋଇପାରେ । ଯକୃତ ସମସ୍ୟା ଥିଲେ ଏହାକୁ ଦେବା ଉଚିତ ନୁହେଁ । ^[୧] ଗର୍ଭାବସ୍ଥାରେ ରିବାଭିରିନ ସ‌ହିତ ଦେଲେ ଶିଶୁ ପ୍ରତି ବିପଦ ହୁଏ, ସୋଫୋସବୁଭିର ସ‌ହିତ ଏହାର ନିରାପତ୍ତା ସ୍ପଷ୍ଟ ହୋଇନାହିଁ ।^[୧]^[୫] ସିମେପ୍ରେଭିର ଏକ ଏଚସିଭି ପ୍ରୋଟିଏଜ ଇନହିବିଟର (HCV protease inhibitor) ।^[୧]

ମେଡିଭିର ଏବି (Medivir AB) ଓ ଜାନସେନ ଫର୍ମାସିଉଟିକାଲ (Janssen Pharmaceutica) ଏହି ସିମେପ୍ରେଭିର ଔଷଧ ପ୍ରସ୍ତୁତ କରିଛନ୍ତି । ^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ସନ ୨୦୧୩ରେ ଏହା ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ସ୍ୱୀକୃତ ହୋଇଥିଲା । ^[୭] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ଚିଠାରେ ଅଛି ଯାହା ମୌଳିକ ସ୍ୱାସ୍ଥ୍ୟ ସିସ୍ଟମ ନିମନ୍ତେ ଅତି ମହତ୍ତ୍ୱପୂର୍ଣ୍ଣ । ^[୮] ଏହା ଜେନେରିକ ଔଷଧ ନାମରେ ସନ ୨୦୧୫ ସୁଦ୍ଧା ଉପଲବ୍‌ଧ ହୋଇନାହିଁ । ^[୫] ଇଂଲଣ୍ଡରେ ସନ ୧୦୧୫ରେ ସିମେପ୍ରେଭିର, ରିବିଭିରିନ ଓ ପେଜିଣ୍ଟରଫେରନ-ଆଲଫାର ଗୋଟିଏ କୋର୍ଷର ଖର୍ଚ୍ଚ ପ୍ରାୟ ୨୯,୭୦୦ ପାଉଣ୍ଡ ।^[୯] ୟୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ସିମାପ୍ରେଭିର ଓ ସୋଫୋସବୁଭି କୋର୍ଷର ଖର୍ଚ୍ଚ ପ୍ରାୟ ୧୭୧,୦୦୦ ଡଲାର ଓ ସେଥିରୁ କେବଳ ସିମେପ୍ରେଭିର ମୂଲ୍ୟ ପ୍ରାୟ ୬୬,୩୬୦ ଆମେରିକୀୟ ଡଲାର ।^[୧୦]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Simeprevir". The American Society of Health-System Pharmacists. Retrieved Nov 30, 2016.
↑ "Initial treatment of HCV infection". www.hcvguidelines.org. October 2016. Retrieved 1 December 2016.
↑ Majumdar, A; Kitson, MT; Roberts, SK (June 2016). "Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis". Alimentary pharmacology & therapeutics. 43 (12): 1276–92. PMID 27087015.
↑ Brochot, E; Helle, F; François, C; Castelain, S; Capron, D; Nguyen-Khac, E; Duverlie, G (April 2015). "Which therapeutic option for hepatitis C virus genotype 1?". Scandinavian journal of gastroenterology. 50 (4): 470–8. PMID 25396710.
↑ ^୫.୦ ^୫.୧ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 80. ISBN 9781284057560.
↑ Grubbs, Robert H.; O'Leary, Daniel J. (2015). Handbook of Metathesis, Volume 2: Applications in Organic Synthesis (in ଇଂରାଜୀ). John Wiley & Sons. p. 699. ISBN 9783527694020.
↑ DUGUM, M.; O'SHEA, R. "Hepatitis C virus: Here comes all-oral treatment". Cleveland Clinic Journal of Medicine. 81 (3): 159–172. doi:10.3949/ccjm.81a.13155. PMID 24591471.^{[permanent dead link]}
↑ "Essential Medicines WHO Model List, 19th edition, April 2015" (PDF). World Health Organization. 2015.
↑ "Janssen will cover cost of unsuccessful hepatitis C treatment". PMLive. 16 January 2015. Retrieved 1 December 2016.
↑ Smith, Michael (28 February 2015). "HCV Drugs Costly but Cure Might Not Be". MedPageToday. Retrieved 1 December 2016.

[AHFS2016-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Simeprevir". The American Society of Health-System Pharmacists. Retrieved Nov 30, 2016.

[2] "Initial treatment of HCV infection". www.hcvguidelines.org. October 2016. Retrieved 1 December 2016.

[3] Majumdar, A; Kitson, MT; Roberts, SK (June 2016). "Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis". Alimentary pharmacology & therapeutics. 43 (12): 1276–92. PMID 27087015.

[4] Brochot, E; Helle, F; François, C; Castelain, S; Capron, D; Nguyen-Khac, E; Duverlie, G (April 2015). "Which therapeutic option for hepatitis C virus genotype 1?". Scandinavian journal of gastroenterology. 50 (4): 470–8. PMID 25396710.

[Ric2015-5] ୫.୦ ^୫.୧ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 80. ISBN 9781284057560.

[6] Grubbs, Robert H.; O'Leary, Daniel J. (2015). Handbook of Metathesis, Volume 2: Applications in Organic Synthesis (in ଇଂରାଜୀ). John Wiley & Sons. p. 699. ISBN 9783527694020.

[Cle2013-7] DUGUM, M.; O'SHEA, R. "Hepatitis C virus: Here comes all-oral treatment". Cleveland Clinic Journal of Medicine. 81 (3): 159–172. doi:10.3949/ccjm.81a.13155. PMID 24591471.^{[permanent dead link]}

[WHOlist-8] "Essential Medicines WHO Model List, 19th edition, April 2015" (PDF). World Health Organization. 2015.

[9] "Janssen will cover cost of unsuccessful hepatitis C treatment". PMLive. 16 January 2015. Retrieved 1 December 2016.

[10] Smith, Michael (28 February 2015). "HCV Drugs Costly but Cure Might Not Be". MedPageToday. Retrieved 1 December 2016.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

Clinical data

Pronunciation	sim-E-pre-vir
Trade names	ବ୍ୟବସାୟୀକ ନାମ - ଓଲିସିଓ, ସୋଭ୍ରିଆଡ, ଗାଲେକ୍ସୋସ ଓ ଅନ୍ୟାନ୍ୟ ।
Synonyms	TMC435; TMC435350
AHFS/Drugs.com	monograph
MedlinePlus	a614013
Pregnancy category	US: C and X^[୧]
Routes of administration	ପାଟିରେ କ୍ୟାପସୁଲ ଆକାରରେ
ATC code	J05AE14 (WHO)
Legal status
Legal status	US: Rx-କେବଳ ପ୍ରେସକ୍ରିପନରେ ℞-କେବଳ ପ୍ରେସକ୍ରିପନରେ
Pharmacokinetic data
Bioavailability	୬୨% (under fed conditions)
Protein binding	>୯୯.୯%
Metabolism	ଯକୃତ (CYP3A, CYP2C8, CYP2C19)
Elimination half-life	୧୦–୧୩ ଘଣ୍ଟା (ଏଚସିଭି-ଅଣସଂକ୍ରମିତ ଲୋକ), ୪୧ ଘଣ୍ଟା (ଏଚସିଭି-ସଂକ୍ରମିତ ଲୋକ)
Excretion	ମଳ (୯୧%), ପରିସ୍ରା (<୧%)
Identifiers
IUPAC name (2R,3aR,10Z,11aS,12aR,14aR)-N-(Cyclopropylsulfonyl)-2-{[2-(4-isopropyl-1,3-thiazol-2-yl)-7-methoxy-8-methyl-4-quinolinyl]oxy}-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxamide
CAS Number	923604-59-5
PubChem CID	56928193
IUPHAR/BPS	7367
DrugBank	DB06290
ChemSpider	23331536
UNII	9WS5RD66HZ
KEGG	D10081
ChEMBL	CHEMBL501849
NIAID ChemDB	489101
ECHA InfoCard	100.215.933
Chemical and physical data
Formula	C₃₈H₄₇N₅O₇S₂
Molar mass	749.94 g/mol
3D model (JSmol)	Interactive image
SMILES Cc1c(ccc2c1nc(cc2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)c7nc(cs7)C(C)C)OC
InChI InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1 Key:JTZZSQYMACOLNN-VDWJNHBNSA-N